Dec 7, 2021
NCT04808037: Phase 1/2: Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM (BelaRd)
BelaRd Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma (BelaRd) NCT04808037:...
302
Dec 7, 2021
What is the best diet for myeloma patients to build a strong immune system? IMF
What is the best diet for myeloma patients to build a strong immune system? IMF: International Myeloma Foundation Learn more:...
119
Dec 7, 2021
Miami Myeloma MRD 2021 Virtual Meeting October 13, 2021
The Miami Myeloma MRD 2021 Virtual Meeting will take place on October 13, 2021 at 9am EDT/2pm BST/3pm CEST. Organized by the Multiple...
209
Dec 6, 2021
63RD ASH ANNUAL MEETING AND EXPOSITION -Atlanta, GA December 11-14, 2021
63RD ASH ANNUAL MEETING AND EXPOSITION December 11-14, 2021 Georgia World Congress Center - Atlanta, GA In-person and virtual...
359
Dec 6, 2021
NCCN Patient Webinar: Multiple Myeloma
NCCN Patient Webinar: Multiple Myeloma Learn more: https://www.nccn.org/patientresources/patient-resources/patient-webinars/multiple-myeloma
147
Dec 6, 2021
Multiple Myeloma Research Foundation - MMRF - Learn Your Labs | High Impact Topic (HIT)
Learn Your Labs: This video provides information on laboratory tests that myeloma patients may undergo. Learn about why and how the tests...
71
Dec 4, 2021
NCT05027594: Phase 1: Study of NMS-03597812 in Adult Pts With Relapsed or Refractory Myeloma
PERK Inhibitor NCT05027594: Phase 1: Ph I Study of NMS-03597812 in Adult Pts With Relapsed or Refractory Multiple Myeloma Ph I Study of...
323
Dec 4, 2021
NCT04937777: EMN 23 - Study on the Management & Outcome of Systemic AL Amyloidosis in Europe
EMN 23 NCT04937777: A Study on the Management and Outcome of Patients With Systemic AL Amyloidosis in Europe NCT04937777: A Study on the...
56
Dec 3, 2021
NIH: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Patient Version
www.cancer.gov NIH: NATIONAL CANCER INSTITUTE Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Patient Version Plasma...
84
Dec 3, 2021
NCT05083169: Phase 3 - Tec-Dara Vs DPd Vs DVd in Relapsed or Refractory Myeloma - MajesTEC-3
MajesTEC-3 A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and...
1,044
Dec 2, 2021
BMT CTN Immune and Cellular Therapy in Multiple Myeloma Workshop Friday Jan 7th, 2022-10 am - 1 pm
BMT CTN Immune and Cellular Therapy in Multiple Myeloma Workshop Friday Jan 7th, 2022 10 am - 1 pm ET Register here: ...
100
Dec 2, 2021
NCT05028348: Phase 3: EMN 29 - Selinexor, Pom, Dex (SPd) Vs Elotuzumab, Pom, Dex in RRMM Myeloma
EMN 29 NCT05028348: Phase 3: A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide,...
444
Dec 2, 2021
FDA Approved for RRMM:Daratumumab and Hyaluronidase-fihj(Darzalex Faspro) + Kyprolis & Dexamethasone
FDA Approved for RRMM: Daratumumab and Hyaluronidase-fihj (Darzalex Faspro) + Kyprolis & Dexamethasone FDA approves Darzalex Faspro,...
216
Dec 1, 2021
NCT05020236: Phase 3-MagnetisMM-5: Elranatamab (PF-06863135) Vs & Elranatamab/Dara VS Dara/Pom/Dex
MagnetisMM-5 Relapsed Refractory Multiple Myeloma NCT05020236: Phase 3 - MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and...
839
Dec 1, 2021
NCT05060627: Phase 1/2: Belantamab Mafodotin + Kd RRMM Multiple Myeloma, Refractory to Lenalidomide
NCT05060627: An Open Label, Multicenter, Phase I/II Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed...
146
Dec 1, 2021
NCT05139225: Phase 1: A Study of TTI-621 and TTI-622 in Combination With Daratumumab RRMM
NCT05139225: Phase 1: A Study of TTI-621 and TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma A...
301
Dec 1, 2021
Patient Symposium - MCRT Webcast Myeloma Crowd Round Table, 06/26/2021
MCRT Webcast - Myeloma Crowd Round Table Myeloma Crowd Round Tables program Myeloma Crowd by HealthTree MCRT Webcast Jun 26, 2021 ASCO...
83
Dec 1, 2021
NCT05123131: Phase 2: Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma (Isa-RVD)
NCT05123131: Phase 2: Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma (Isa-RVD) Isa-RVD Study in Patients With Newly...
194
Dec 1, 2021
Abecma: CART Cell Therapy -FDA Approves First Cell-Based Gene Therapy for Adult Patients with RRMM
For Immediate Release: March 27, 2021: The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene...
370